Indian company Natco Pharma Limited will manufacture a copy-cat version of Bayer’s cancer treatment drug Nexavar (Sorafenib) in the first case of compulsory licencing there following a decision by the Indian Patent Office on Monday The Natco Pharma generic version of Nexavar (Sorafenib), used in the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer, is expected to be up to 97 percent cheaper than the Bayer product According to media reports the Natco Pharma generic version of Nexavar (Sorafenib) will sell for around $US175) for a 120-capsule, one-month course of treatment, compared to about $5,500 for the Bayer branded product. The ruling will see Natco Pharma may a 6 percent royalty on net sales … Continue reading →